In the Netherlands, the use of trastuzumab for the adjuvant treatment of patients with HER2-positive early breast cancer was estimated to be €5,828 per quality adjusted life year (QALY) gained (using a health care perspective). The gene discussed is ERBB2; the disease is breast cancer.